XAIR Valuation

Beyond Air Inc

Add to Watchlist

Advanced Chart

2.350

+0.12(5.381%)1D

Overview
Forecast
Valuation
Earnings

XAIR Relative Valuation

XAIR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XAIR is overvalued; if below, it's undervalued.

Historical Valuation

Beyond Air Inc (XAIR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.62 is considered Undervalued compared with the five-year average of -2.39. The fair price of Beyond Air Inc (XAIR) is between 11.33 to 20.44 according to relative valuation methord. Compared to the current price of 2.23 USD , Beyond Air Inc is Undervalued By 80.32%.

Relative Value

Fair Zone

11.33-20.44

Current Price：2.23

80.32%

Undervalued

-0.78

Trailing

Forward

0.00

EV/EBITDA

Beyond Air Inc. (XAIR) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.14. The thresholds are as follows: Strongly Undervalued below -11.43, Undervalued between -11.43 and -6.79, Fairly Valued between 2.50 and -6.79, Overvalued between 2.50 and 7.14, and Strongly Overvalued above 7.14. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.70

EV/EBIT

Beyond Air Inc. (XAIR) has a current EV/EBIT of -0.70. The 5-year average EV/EBIT is -1.76. The thresholds are as follows: Strongly Undervalued below -7.61, Undervalued between -7.61 and -4.68, Fairly Valued between 1.17 and -4.68, Overvalued between 1.17 and 4.09, and Strongly Overvalued above 4.09. The current Forward EV/EBIT of -0.70 falls within the Historic Trend Line -Fairly Valued range.

0.62

Beyond Air Inc. (XAIR) has a current PS of 0.62. The 5-year average PS is 40.20. The thresholds are as follows: Strongly Undervalued below -115.87, Undervalued between -115.87 and -37.83, Fairly Valued between 118.23 and -37.83, Overvalued between 118.23 and 196.26, and Strongly Overvalued above 196.26. The current Forward PS of 0.62 falls within the Historic Trend Line -Fairly Valued range.

-1.02

P/OCF

Beyond Air Inc. (XAIR) has a current P/OCF of -1.02. The 5-year average P/OCF is -2.33. The thresholds are as follows: Strongly Undervalued below -11.24, Undervalued between -11.24 and -6.78, Fairly Valued between 2.13 and -6.78, Overvalued between 2.13 and 6.59, and Strongly Overvalued above 6.59. The current Forward P/OCF of -1.02 falls within the Historic Trend Line -Fairly Valued range.

-0.32

P/FCF

Beyond Air Inc. (XAIR) has a current P/FCF of -0.32. The 5-year average P/FCF is -1.69. The thresholds are as follows: Strongly Undervalued below -8.17, Undervalued between -8.17 and -4.93, Fairly Valued between 1.54 and -4.93, Overvalued between 1.54 and 4.78, and Strongly Overvalued above 4.78. The current Forward P/FCF of -0.32 falls within the Historic Trend Line -Fairly Valued range.

Beyond Air Inc (XAIR) has a current Price-to-Book (P/B) ratio of 1.05. Compared to its 3-year average P/B ratio of 2.37 , the current P/B ratio is approximately -55.48% higher. Relative to its 5-year average P/B ratio of 3.36, the current P/B ratio is about -68.64% higher. Beyond Air Inc (XAIR) has a Forward Free Cash Flow (FCF) yield of approximately -308.65%. Compared to its 3-year average FCF yield of -132.16%, the current FCF yield is approximately 133.55% lower. Relative to its 5-year average FCF yield of -84.28% , the current FCF yield is about 266.22% lower.

1.05

P/B

Median3y

2.37

Median5y

3.36

-308.65

FCF Yield

Median3y

-132.16

Median5y

-84.28

Competitors Valuation Multiple

The average P/S ratio for XAIR's competitors is 1.27, providing a benchmark for relative valuation. Beyond Air Inc Corp (XAIR) exhibits a P/S ratio of 0.62, which is -50.95% above the industry average. Given its robust revenue growth of 157.69%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BioRestorative Therapies Inc

Ekso Bionics Holdings Inc

Meihua International Medical Technologies Co Ltd

Loss

12.76M

POAI.O

Predictive Oncology Inc

1.01

-96.01%

11.55M

Performance Decomposition

Market capitalization of XAIR decreased by 71.26% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 683.00K to 1.76M.

The secondary factor is the Margin Expansion, contributed -75.99%to the performance.

Overall, the performance of XAIR in the past 1 year is driven by Revenue Growth. Which is more sustainable.

157.69%

683.00K → 1.76M

Revenue Growth

-75.99%

-1.91K → -458.98

Margin Expansion

-152.96%

0.41 → -0.22

P/E Change

-71.26%